Publications by authors named "Wendanqi Liang"
Article Synopsis
- * A key challenge in utilizing RNA therapies is effectively delivering them to the central nervous system through the blood-brain barrier (BBB).
- * This review emphasizes therapeutic RNA, particularly small interfering RNAs (siRNAs), and explores various strategies for treating neurodegenerative diseases to facilitate their clinical application.
Article Synopsis
- - Alzheimer's disease is a progressive brain disorder marked by the buildup of harmful proteins like amyloid plaques and tau tangles, which disrupt normal lysosomal functions needed for protein breakdown and cellular balance.
- - There's growing evidence suggesting that improving lysosomal function could help alleviate Alzheimer's symptoms, but current drug treatments face challenges related to effectiveness and delivery.
- - This review discusses the use of nanomaterials, such as polymeric nanomaterials and nanoemulsions, to enhance lysosomal activity in Alzheimer's treatment, highlighting innovative strategies and the potential for future therapies.
Article Synopsis
- Age plays a major role in the development of Alzheimer's Disease (AD), and senolysis has shown potential in treating age-related diseases, including AD.
- SSK1, a prodrug activated by the enzyme β-gal, targets and eliminates senescent cells, enhancing its effectiveness against AD despite the challenges posed by the blood-brain barrier (BBB).
- SSK1-loaded lipid nanoparticles (SSK1-NPs) have been created to improve BBB penetration, successfully reducing senescence-related gene expression, decreasing amyloid-beta accumulation, and improving cognitive function in aged AD mice, indicating great promise for AD therapy.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder, which is not just confined to the older population. Although developments have been made in AD treatment, various limitations remain to be addressed. These are partly contributed by biological hurdles, such as the blood-brain barrier and peripheral side effects, as well as by lack of carriers that can efficiently deliver the therapeutics to the brain while preserving their therapeutic efficacy.
View Article and Find Full Text PDFWith the increase of population aging, the number of Alzheimer's disease (AD) patients is also increasing. According to current estimates, approximately 11% of people over 65 suffer from AD, and that percentage rises to 42% among people over 85. However, no effective treatment capable of decelerating or stopping AD progression is available.
View Article and Find Full Text PDFAge is the strongest risk factor for Alzheimer's disease (AD). In recent years, the relationship between aging and AD has been widely studied, with anti-aging therapeutics as the treatment for AD being one of the mainstream research directions. Therapeutics targeting senescent cells have shown improvement in AD symptoms and cerebral pathological changes, suggesting that anti-aging strategies may be a promising alternative for AD treatment.
View Article and Find Full Text PDF